PMDA — authorised 25 September 2020
- Marketing authorisation holder: Kaken Pharmaceutical
- Status: approved
PMDA authorised Ecclock on 25 September 2020
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. PMDA authorised it on 25 September 2020.
Kaken Pharmaceutical holds the Japanese marketing authorisation.